TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07403188: A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Sponsor: Kyverna Therapeutics · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 70 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT07403188 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07403188 Rescue Dossier →